Aclaris Therapeutics, Inc. (“Aclaris”) (NASDAQ: ACRS), a dermatologist-led, biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News Mergers and Acquisitions

Aclaris Therapeutics (ACRS) Reports Q2 Loss of $0.56/ShareAugust 8, 2017 7:27 AM Aclaris Therapeutics Acquires Confluence Life Sciences, Inc.August 8, 2017 7:00 AM